PL EN


Preferences help
enabled [disable] Abstract
Number of results
2009 | 63 | 2 | 78-84
Article title

Monooksygenazy zależne od cytochromu P-450 oraz enzymy II fazy przemian ksenobiotykow w łożysku

Content
Title variants
EN
P-450 cytochrome-dependent monooxygenases and phase II
Languages of publication
PL
Abstracts
EN
The fi rst part of this paper contains the discussion of the organization of the basic P-450 cytochrome-dependent monooxygenases including the functional diff erences resulting from their location in the microsomal and mitochondrial fractions, the basic stages of the pertinent metabolic changes, and also, the mechanisms of induction of the Cyp.-450 in the families 1,2,3 and 4. In the next part, the current state of knowledge on monooxygenases in the placental cells has been presented. Attention has been drawn to the fact that despite the low contents of both mRNA and CYP-450 protein in the families 1,2,3 and 4 in syncytiotrophoblast cells at the level of just several percent hepatocytes, this system may perform an important role in the release of indirect toxic metabolites , thus posing threat to the lives of either the embryo or the fetus, particularly in the fi rst trimester of pregnancy. These risks substantially increase in situations where the pregnant woman has had contact with medicines, alcohol, narcotics or tobacco smoke, which are found to be eff ective CYP-450 inducers or inhibitors. In the fi nal part, the activity of Phase II xenobiotic metabolism enzymes in the placenta has been discussed, including UDP-gluconylotransferase, 5-glutation transferase, and sulfotransferases.
PL
W części pierwszej omówiono organizację podstawowych ogniw monooksygenaz zależnych od cytochromu P-450, różnice funkcjonalne wynikające z ich posadowienia we frakcji mikrosomalnej i mitochondrialnej komórek, podstawowe etapy realizowanych przemian, a także mechanizmy indukcji rodziny 1,2,3 i 4 CYP.-450. Następnie przedstawiono aktualny stan wiedzy na temat monooksygenaz w komórkach łożyska. Zwrócono uwagę, iż pomimo niskich zawartości mRNA i białka CYP-450 rodziny 1,2 oraz 3 w komórkach syncytiotrofoblastu na poziomie zaledwie kilkuprocentowym hepatocytów, układ ten może spełniać ważną rolę w uwalnianiu toksycznych metabolitów pośrednich, stwarzając zagrożenie dla zdrowia i rozwoju zarodka oraz płodu, zwłaszcza w I trymestrze ciąży. Owe zagrożenia zdecydowanie wzrastają w warunkach kontaktu ciężarnej kobiety z lekami, dymem papierosowym, alkoholem, narkotykami, które są efektywnymi induktorami lub inhibitorami CYP-450. Omówiono także aktywność w łożysku enzymów II fazy przemian ksenobiotyków, w tym: UDP-glukonylotransferazy, transferazy S-glutationowej i sufotransferaz.
Discipline
Publisher

Year
Volume
63
Issue
2
Pages
78-84
Physical description
Contributors
  • Klinika Położnictwa i Ginekologii, Katedry Położnictwa i Ginekologii SUM, ul. Medykow 14, 40-752 Katowice, tel.: +48 32 789 47 01, fax +48 32 252 53 02, wloch@pron.pl
References
  • 1. Kamiński M., Wiaderkiewicz R. The role of the liver in xenobiotic biotransformation. Part II. Xenobiotic metabolism in the liver mediated by cytochrome P-450 – dependent monooksygenases. Problems of Forensic Sci. 2008; 73: 7-20.
  • 2. Parkinson A. Biotransformation of xenobiotics. W: Casarett and Doull`s Toxicology (red. Klaassen C), Mc Graw-Hill, Inc, University of Kansas Medical Center. 2001: 133-224.
  • 3. Kato S., Bowman E., Harrington A i wsp. Human lung carcinogen – DNA adduct levels mediated by genetic polymorphisms in vivo. J.Pat.Cancer Inst.1995; 87: 902-907.
  • 4. Kamiński M., Wiaderkiewicz R., Orschulik M. Układ monooksygenaz zależnych od cytochromu P-450 w metabolizacji ksenobiotyków i endogennych produktów przemian. Medycyna Pracy. 2001; 5: 19- 26.
  • 5. Nelson D., Kamataki T., Waxman D. i wsp. The P-450 superfamily: Update on new seguences, gen mapping, accesion numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol. 1993; 12: 1-51.
  • 6. Negishi M., Uno T., Darden T i wsp. (1996). Structural fl exibility and functional versatility of mamallian P-450 enzymes. FASEB J. 1966; 10: 683-689.
  • 7. Schlichting I., Derendzen J., Chu K. i wsp. The catalytic pathway of cytochrome P-450 cam at atomic resolution. Science. 2000; 287: 1615-1622.
  • 8. Denison M.S., Nagy S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Ann. Rev. Pharmacol. Toxicol., 2003, 43, 309-343.
  • 9. Czekaj P. Phenobarbital induced expression of cytochrome P-450 gens. Acta Bioch. Pol. 2000; 47: 1093-1105.
  • 10. Mimura J and Fujii-Kurijama Y. Functional role of AhR in the expression of toxic eff ects by TCDD. Biochim. Biophys. Acta. 2003; 1619: 263-268.
  • 11. Nebert D.W., Dalton T.P., Okey A.B., Gonzales F.J. Role of aryl hydrocarbon receptor – mediated induction of the CYP- 1 enzymes in environmental toxicity and cancer. J.Biol. Chem. 2004; 279: 23847- 23850.
  • 12. Czekaj P., Wiaderkiewicz A., Florek E., Wiaderkiewicz R. Expression of cytochrome CYP2B1/2 in nonpregnant, pregnant and fetal rats exposed to tobacco smoke. Acta Biochem. Pol. 2000; 4: 1115- 1127.
  • 13. Chien J., Thummel K., Slaterry J. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos. 1997; 25: 1165-1175.
  • 14. Hahn M. Aryl hydrocarbon receptors: diversity and evolution. Chem. Biol. Interact. 2002; 141: 131-138.
  • 15. Waxman P. P-450 gen regulation by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR and PPAR. Acta Biochem. Biophys. 1999; 369: 11-23.
  • 16. Nebert D.W, Roe A.L., Dieter M.Z i wsp. Role of aromatic hydrocarbon (Ah) gen battery in oxidative stress response, cell control and apoptosis. Biochem. Pharmacol. 2000; 59: 65-85.
  • 17. Shweitz S. Drug metabolizing enzyme: mechanism and function. Current Drug Metab. 2000; 1: 107-132.
  • 18. Dogra S., Whitelan M., May B. Transcriptional activation of cytochrome P-450 genes by diff erent classes of chemical inducers. Clin. Exp. Pharmacol. Physiol. 1998; 25: 1-9.
  • 19. Kliewer S., Lehmann J., Willson T. Orphan nuclear receptors: shifting endocrinology into reverse. Science. 1999; 284: 757-760.
  • 20. Lehmann J., Mc Kee D., Willson T i wsp. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gen expression and cause drug interactions. J. Clin. Invest. 1998; 102: 1016- 1102.
  • 21. Johnoson E.F., Palmer C.N.A., Griffi n K.J. i wsp. Role of the peroxisome proliferator - activated receptor cytochrome P-4504A gene regulations. FASEB. J. 1996; 10: 1241-1248.
  • 22. Megis R.A and Rayan K.J. Cytochrome P-450 and steroid biosynthesis in the human placenta. Biochem. Biophys. Acta. 1968; 1512: 476-482.
  • 23. Pasanen M., Pelkonen O. Xenobiotic steroid metabolizing monooxygenases catalysed by cytochrome P-450 and glutathione S-transferase conjugations in the human placenta and their relatonships to maternal cigarette smoking. Placenta. 1996; 11: 75-85.
  • 24. Collierr A.C., Ganley N.A., Tingle M.D. UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem. Pharmacol. 2002; 63: 409-419.
  • 25. Paxton M.R., Keelan J.A. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. 2004; 8: 487-514.
  • 26. Schuetz J.D., Kauma S., Guzelian P.S. Identifi cation of the fetal liver cytochrome P3A7 in human endometrium and placenta. J. Clin. Invest. 1993; 92: 1018-1024.
  • 27. Whyatt R.M., Gapte S.J., Cosma G., Bell D.A., Jędrychowski W., Nahrendorf J., Randall M.C., Cooper T.B., Ottman R., Tang D., Tsai W., Dickey Ch.P., Manchester D.K., Croft F., Perera F.P. CYP1A1 mesenger RNA levels in placental tissue as a biomarker of environmental exposure. Cancer Epidemiology, Biomarkers and Prevention. 1995; 4: 147-153.
  • 28. Hakkola J., Pasanen M., Hukkanen J., Palkonen O., Maenpaa J., Edwards R.J., Boobis A.R., Raunio H. Expression of xenobiotic – metabolizing cytochrome P-450 forms in human full-term placenta. Biochem. Pharmacol. 1996; 51: 403-411.
  • 29. Hakkola J., Raunio H., Purkunen R., Pelkonen O., Saarikoski S., Cresteil T., Pasanen M. Detection of cytochrome P-450 gen expression in human placenta at fi rst trimester of pregnancy. Biochem. Pharmacol. 1996; 52: 379-383.
  • 30. Pasanen M., Stenback F., Park S.S., Gelmoin H.V., Pelkonen O. Immunohistochemical detection of human placental cytochrome P-450 – associated mono-oxygenases system inducible by maternal cigarette smoking. Placenta. 1988; 9: 267-275.
  • 31. Pasanen M. The expression and regulation of drug metabolism in human placenta. Adv. Drug. Deliv. Rev. 1999; 38: 81-97.
  • 32. Pasanen M., Pelkolen O. The expression and environmental regulation of P-450 enzymes in human placenta. Crit. Rev. Toxicol. 1994; 24: 211-229.
  • 33. Syme M.R., Paxton J.W. and Keelan J.A. Drug transfer and metabolism by the human placenta. Clin. Pharmacol. 2004; 43: 487-514.
  • 34. Paaki P., Stockmann D., Kantola M., Wagner P., Lauper U., Huch R., Elovaara E., Kirkinen P., Pasanen M. Maternal drug abuse and human term placental xenobiotic and steroid metabolizing enzymes in vitro. Environ. Helth Perspect. 2000; 2: 141-145.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-f8298528-8d6a-41f9-ac22-0045a6786ec7
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.